"Woman," "elderly," and "disabled" were among a list of banned words reportedly circulating within the FDA, which the White ...
The FDA has approved Ctexli for the treatment of cerebrotendinous xanthomatosis (CTX), a rare lipid storage disease, in ...
Chenodiol -- a naturally occurring human bile acid also known as chenodeoxycholic acid -- is the first FDA-approved drug ...
Hormone pellets are a type of hormone replacement therapy (HRT) sometimes taken for menopause symptom relief. Pros include convenience and improved symptoms, but there are also a few cons to this ...
Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of the ...
Ozempic and Wegovy, the widely popular forms of semaglutide sold to treat diabetes and obesity, have officially been removed ...
After asset purchase from Travere, Mirum's Ctexli crosses FDA finish line in rare metabolic disorder
The approval makes chenodiol—already cleared for decades to treat radiolucent gallstones under the brand name Chenodal—the ...
Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug ...
Heart disease, also called cardiovascular disease, can have serious consequences. It's the leading cause of death for adults in the U.S. Medical devices approved by the U.S. Food and Drug ...
The FDA has now resolved the shortages of Novo Nordisk and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...
Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration said on Friday.
Mirum Pharmaceuticals' Ctexli wins FDA approval for CTX, a rare lipid storage disease. The company projects 2025 global sales of $420–$435 million.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback